DE69706825T3 - Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen - Google Patents

Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen Download PDF

Info

Publication number
DE69706825T3
DE69706825T3 DE69706825T DE69706825T DE69706825T3 DE 69706825 T3 DE69706825 T3 DE 69706825T3 DE 69706825 T DE69706825 T DE 69706825T DE 69706825 T DE69706825 T DE 69706825T DE 69706825 T3 DE69706825 T3 DE 69706825T3
Authority
DE
Germany
Prior art keywords
papillomavirus
region
polypeptide
dna fragment
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69706825T
Other languages
German (de)
English (en)
Other versions
DE69706825T2 (de
DE69706825D1 (de
Inventor
Jean-Marc Balloul
Nadine Bizouarne
Marie-Paule Kieny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9494633&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69706825(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Transgene SA filed Critical Transgene SA
Publication of DE69706825D1 publication Critical patent/DE69706825D1/de
Publication of DE69706825T2 publication Critical patent/DE69706825T2/de
Application granted granted Critical
Publication of DE69706825T3 publication Critical patent/DE69706825T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69706825T 1996-07-30 1997-07-29 Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen Expired - Lifetime DE69706825T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9609584 1996-07-30
FR9609584A FR2751879B1 (fr) 1996-07-30 1996-07-30 Composition pharmaceutique contre les tumeurs et infections a papillomavirus
PCT/FR1997/001412 WO1998004705A1 (fr) 1996-07-30 1997-07-29 Composition pharmaceutique contre les tumeurs et infections a papillomavirus

Publications (3)

Publication Number Publication Date
DE69706825D1 DE69706825D1 (de) 2001-10-25
DE69706825T2 DE69706825T2 (de) 2002-05-02
DE69706825T3 true DE69706825T3 (de) 2006-08-24

Family

ID=9494633

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69706825T Expired - Lifetime DE69706825T3 (de) 1996-07-30 1997-07-29 Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen
DE69728914T Expired - Lifetime DE69728914T2 (de) 1996-07-30 1997-07-29 Pharmazeutische Zusammensetzung gegen durch Papillomaviren verursachte Tumoren und Infektionen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69728914T Expired - Lifetime DE69728914T2 (de) 1996-07-30 1997-07-29 Pharmazeutische Zusammensetzung gegen durch Papillomaviren verursachte Tumoren und Infektionen

Country Status (12)

Country Link
EP (2) EP1149910B1 (cg-RX-API-DMAC7.html)
JP (2) JP4070815B2 (cg-RX-API-DMAC7.html)
AT (2) ATE205881T1 (cg-RX-API-DMAC7.html)
AU (1) AU736720B2 (cg-RX-API-DMAC7.html)
CA (1) CA2234263C (cg-RX-API-DMAC7.html)
DE (2) DE69706825T3 (cg-RX-API-DMAC7.html)
DK (2) DK1149910T3 (cg-RX-API-DMAC7.html)
ES (2) ES2215805T3 (cg-RX-API-DMAC7.html)
FR (1) FR2751879B1 (cg-RX-API-DMAC7.html)
HK (1) HK1043809B (cg-RX-API-DMAC7.html)
PT (2) PT862634E (cg-RX-API-DMAC7.html)
WO (1) WO1998004705A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
EP1089758A1 (fr) * 1998-06-26 2001-04-11 Aventis Pasteur Immunisation a ciblage mucosal
DK2029756T3 (en) 2006-06-20 2017-02-13 Transgene Sa PROCEDURE FOR PREPARING POXVIRA AND POXVIRUS COMPOSITIONS
AU2010206195B2 (en) 2009-01-20 2016-03-10 Transgene Sa Soluble ICAM-1 as biomarker for prediction of therapeutic response
ES2555858T3 (es) 2009-03-24 2016-01-11 Transgene Sa Biomarcador para el control de pacientes
PL2419728T3 (pl) 2009-04-17 2014-05-30 Transgene Sa Biomarker do monitorowania pacjentów
US8609392B2 (en) 2009-05-12 2013-12-17 Transgene S.A. Method for orthopoxvirus production and purification
CN102483405B (zh) 2009-07-10 2015-12-02 特朗斯吉有限公司 用于选择患者的生物标志物及相关方法
IN2012DN01577A (cg-RX-API-DMAC7.html) 2009-07-21 2015-06-05 Transgene Sa
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
KR102507483B1 (ko) 2014-12-01 2023-03-07 트랜스진 안정한 액체 백시니아 바이러스 제제
FR3042121A1 (fr) * 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
EP3624851A1 (en) 2017-05-15 2020-03-25 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
CA3062549A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
AU2019336940B2 (en) 2018-09-06 2025-09-11 Bavarian Nordic A/S Storage improved poxvirus compositions
JP7712284B2 (ja) 2020-03-12 2025-07-23 バヴァリアン・ノルディック・アクティーゼルスカブ ポックスウイルスの安定性を改善する組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2643817B1 (fr) * 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
EP0451550A3 (en) † 1990-03-20 1991-11-06 Behringwerke Aktiengesellschaft Seroreactive epitopes of human papillomavirus (hpv) 16 proteins
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
ES2194839T3 (es) * 1991-07-19 2003-12-01 Univ Queensland Vacuna de papilomavirus.
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
GB9306731D0 (en) * 1993-03-31 1993-05-26 Cancer Res Campaign Tech Vaccines
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide vaccne for papillomavirus
AU712714B2 (en) * 1994-10-03 1999-11-11 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule B7 gene in a recombinant virus expressing system
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
FR2749323B1 (fr) * 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique

Also Published As

Publication number Publication date
EP1149910A1 (fr) 2001-10-31
HK1043809A1 (en) 2002-09-27
EP0862634B1 (fr) 2001-09-19
DK0862634T4 (da) 2006-05-08
WO1998004705A1 (fr) 1998-02-05
DK1149910T3 (da) 2004-08-02
ATE265535T1 (de) 2004-05-15
EP1149910B1 (fr) 2004-04-28
ES2215805T3 (es) 2004-10-16
EP0862634A1 (fr) 1998-09-09
CA2234263A1 (fr) 1998-02-05
CA2234263C (fr) 2009-10-13
DK0862634T3 (da) 2002-01-21
JP2000500662A (ja) 2000-01-25
JP2007254474A (ja) 2007-10-04
AU736720B2 (en) 2001-08-02
ES2163795T5 (es) 2006-07-16
HK1043809B (zh) 2004-12-03
FR2751879A1 (fr) 1998-02-06
JP4070815B2 (ja) 2008-04-02
DE69706825T2 (de) 2002-05-02
AU3855297A (en) 1998-02-20
ES2163795T3 (es) 2002-02-01
PT1149910E (pt) 2004-09-30
DE69706825D1 (de) 2001-10-25
FR2751879B1 (fr) 1998-10-30
DE69728914D1 (de) 2004-06-03
EP0862634B2 (fr) 2006-03-01
DE69728914T2 (de) 2005-04-07
JP4198735B2 (ja) 2008-12-17
PT862634E (pt) 2002-03-28
ATE205881T1 (de) 2001-10-15

Similar Documents

Publication Publication Date Title
DE69826661T2 (de) Antitumorale zusammenstellung von immunogene polypetiden mit veränderter zellokalisierung
DE69706825T3 (de) Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen
US7670607B2 (en) Pharmaceutical compositions for treating papillomavirus tumors and infection
DE69002325T2 (de) Pharmazeutische zusammensetzung zur verhütung oder heilung von durch den papillomavirus induzierten tumoren.
DE69529748T2 (de) Polynukleotide vakzine gegen den papilloma virus
DE69636068T2 (de) Virale zubereitungen, vektoren, immunogene und impfstoffe
DE60314541T2 (de) Mindestens zwei ati promotoren enthaltendes rekombinantes pockenvirus
DE602004009743T2 (de) Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara
DE60129358T2 (de) Genetische immunisierung gegen zervixkarzinom
DE60302848T2 (de) Expression von genen im modifizierten vaccinia virus ankara durch verwendung eines cowpox ati promoter
DE69217614T2 (de) Hybride, lösliche und nicht gespaltene gp160-variante
EP1181381B1 (de) Organ-, gewebs- und zellspezifisches immuntherapeutikum für chronische virale infektionen, sowie entzündliche, degenerative und proliferative erkrankungen insbesondere der leber sowie krebs auf der basis von rekombinantem parapoxvirus
EP1064014B1 (de) Arzneimittel zur vermeidung oder behandlung von papillomavirus-spezifischem tumor
EP1188834B1 (de) Rekombinantes MVA mit der Fähigkeit zur Expression des HER-2/neu-Gens
AU781653B2 (en) Pharmaceutical composition for treating papollomavirus tumour and infection
DE19905883C2 (de) Chimäre Virus-ähnliche Partikel bzw. chimäre Capsomere von BPV
DE19925235A1 (de) Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings